In the management of wet macular degeneration (neovascular AMD), intravitreal injections of anti-VEGF agents (such as ranibizumab, aflibercept, or brolucizumab) are the gold standard. However, there are two main strategies for administering them:
Each approach has specific advantages, disadvantages, and selection criteria. Below, we explain both modalities in detail.
Initial phase: Monthly injections are given until the AMD stabilizes (no fluid on the OCT).
Extension phase: After stabilization, the interval between doses is progressively lengthened (e.g., 6, 8, 10 weeks).
If there is recurrence (new fluid), the interval is shortened.
✔ Reduces the number of visits in stable patients.
✔ Lower risk of reactivation vs. PRN (by maintaining predefined intervals).
✔ Better adherence to treatment (predictable planning).
❌ Some patients receive more injections than necessary (potential overtreatment).
❌ Requires close follow-up to adjust intervals.
Patients with recurrent activity.
Those who prefer fewer visits (e.g., people who travel or live far away).
Initial phase: Same as TAE (monthly injections until stabilization).
Maintenance phase: Injections are suspended and restarted only if there is:
Loss of visual acuity.
Appearance of fluid on OCT.
New neovessels on angiography.
✔ Minimizes the number of injections (only when there is activity).
✔ Lower cost (less medication used).
❌ Higher risk of recurrence (due to delayed retreatment).
❌ More frequent visits (every 4-6 weeks for monitoring).
❌ Possible irreversible retinal damage if reactivation is not detected early.
Patients with low disease activity.
Those with good self-monitoring (e.g., those who use the Amsler grid daily).
Recent evidence favors "Treat and Extend" due to:
Better long-term visual acuity.
Less stress for the patient (no longer waiting for urgent checkups).
PRN may be useful in highly selected cases (patients with low disease activity and close follow-up).